- Home
- CNR vs ELVN Comparison
CNR vs ELVN Comparison
Compare CNR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNR | ELVN |
|---|---|---|
| Founded | 1864 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.2B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNR | ELVN |
|---|---|---|
| Price | $93.99 | $57.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $111.50 | $43.40 |
| AVG Volume (30 Days) | 583.9K | ★ 986.1K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $2,236,311,000.00 | N/A |
| Revenue This Year | $7.26 | N/A |
| Revenue Next Year | $6.83 | N/A |
| P/E Ratio | $32.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $69.72 | $14.79 |
| 52 Week High | $114.80 | $62.32 |
Technical Indicators
Market Signals| Indicator | CNR | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 60.65 | 59.86 |
| Support Level | $83.89 | $25.63 |
| Resistance Level | $96.00 | $62.32 |
| Average True Range (ATR) | 3.39 | 2.69 |
| MACD | 0.58 | -0.29 |
| Stochastic Oscillator | 83.47 | 63.03 |
Price Performance
Historical ComparisonAbout CNR Core Natural Resources Inc.
Core Natural Resources Inc is a producer and exporter of metallurgical and thermal coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The activities of the company involves mining of thermal coal, power generation, and other related activities.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.